This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Vibrational spectroscopy, or infrared (IR) spectroscopy, allows for the identification of functional groups and, due to its low expense and robustness, is often used in teaching labs and the real-time monitoring of reaction progress in difficult to reach environments (high pressure, high temperature, gas phase, phase boundaries). Molecular vibrations are quantized in an analogous manner to electronic wavefunctions, with integer increases in frequency leading to higher energy states. The difference in energy between vibrational states is nearly constant, often falling in the energy range corresponding to infrared photons, because at normal temperatures molecular vibrations closely resemble harmonic oscillators. It allows for the crude identification of functional groups in organic molecules, but spectra are complicated by vibrational coupling between nearby functional groups in complex molecules. Therefore, its utility in structure determination is usually limited to simple molecules. Further complicating matters is that some vibrations do not induce a change in the molecular dipole moment and will not be observable with standard IR absorption spectroscopy. These can instead be probed through Raman spectroscopy, but this technique requires a more elaborate apparatus and is less commonly performed. However, as Raman spectroscopy relies on light scattering it can be performed on microscopic samples such as the surface of a heterogeneous catalyst, a phase boundary, or on a one microliter (μL) subsample within a larger liquid volume.
=== Pregnancy and breastfeeding === The safety of using omeprazole has not been established in pregnant or breastfeeding women. Epidemiological data do not show an increased risk of major birth defects after maternal use of omeprazole during pregnancy.
==== A, Short Order ==== The Unitized Group Ration – A, Short Order (UGR-A SO) consists of meals intended to supplement the UGR-A and expand available food options or feed larger groups, especially where alternate dining facilities or existing meal options are unavailable. Most UGR-A SO meals are based on fast food, pub food, and finger food. The UGR-A SO has the same kilocalorie amount, storage, and minimum shelf life as the regular UGR-A.
Sources: en.wikipedia.org
On Sunday, May 25, 2025, after Filema Duarte still refused to hold elections or resign from office, representative from 117 Cuban Lodges gathered at the National Masonic Temple alongside hundreds of other Freemasons, and demanded his dismissal. Because Filema Duarte had ordered the conference hall to be locked, the Freemasons gathered in the lobby out front of the hall, at the foot of the statue of Carlos Manuel de Céspedes. They sang the National Anthem of Cuba and proceeded to hold the meeting without Filema Duarte or his staff present, and ejected Filema Duarte from the Grand Lodge. Juan Alberto Kessel Linares was reelected as Acting Grand Master of Cuba. Plain-clothes police officers and agents of the State Security Unit were also present at the meeting, capturing photographs and videos of everyone present. Over the course of June, Cuban Freemasons who stood in opposition to Filema Duarte reported that they were under constant surveillance by agents of the government, that their internet was being strategically cut by the government, that power outages were being arranged to target the specific homes of oppositional Freemasons. They also alleged that there were also several "strategic" arrests used as intimidation tactics. On June 14, 2025, Kessel Linares appeared with his Cabinet Elect on the steps of the Grand Lodge of Cuba to hold a press conference, where they denounced the actions of Filema Duarte, of who they said was occupying the office illegally.
In recruitment for residency positions less emphasis is often placed on the number of months a candidate has worked after finishing their internship, but it is common for physicians to work for some time in between internship and residency, much in the same way as between medical school and internship.
== Publications == Phil S. Baran has authored and co-authored approximately 300 research publications with an h-index of 133 and over 60,000 citations. His group's research has been published in journals including Science, Nature, Journal of American Chemical Society (JACS), Angewandte Chemie, and Journal of Organic Chemistry (JOC). Baran has authored the digital interactive reference text The Portable Chemist's Consultant: A Survival Guide for Discovery, Process, and Radiolabeling and contributed chapters and forewords to several scientific publications.
Sources: en.wikipedia.org
Prader–Willi syndrome, with an incidence between 1 in 12,000 and 1 in 15,000 live births, is characterized by hyperphagia and food preoccupations which leads to rapid weight gain in those affected. Bardet–Biedl syndrome MOMO syndrome Leptin receptor mutations Congenital leptin deficiency Melanocortin receptor mutations In children with early-onset severe obesity (defined by an onset before ten years of age and body mass index over three standard deviations above normal), 7% harbor a single locus mutation. One study found that 80% of the offspring of two obese parents were obese, in contrast to less than 10% of the offspring of two parents who were of normal weight. The percentage of obesity that can be attributed to genetics varies from 6% to 85% depending on the population examined.
=== Gene therapy === For patients where an appropriate match for a transplant cannot be found, there have been investigations into the use of gene therapy. Appropriate vectors are selected and modified to express wild type ABCD1, which is then transplanted into the patients using a similar procedure as for a bone marrow or stem cell transplant. Gene therapy has only been tried on a small number of patients, mainly in France. These patients were only considered for gene therapy after there was no HLA match for a traditional transplant. In two reported cases, the gene therapy was successful, with a resolution of the demyelination process up to two years after the procedure. Although the gene therapy was successful in resolving the neurological symptoms, plasma VLCFA levels remained elevated. Elivaldogene autotemcel is pending authorization by the European Commission as of May 2021. While this treatment is effective with 90% of patients being free of major functional disabilities after treatment, it costs $3.0 million per treatment and it comes with several adverse effects including mucositis and alopecia. There are also reports of hematologic cancer development in patients receiving this gene therapy, including myelodysplastic syndrome and acute myeloid leukemia.
== Active site == The spherical carboxypeptidase domain of the catalytic subunit has a circular indentation in the surface which is the location of the active-site groove. The base of the groove is formed by 3 β-sheets while the walls of the groove are lined with α-helices. The electron density in the middle of the groove allows a space for the zinc ion cofactor to bind. The P1' residue of the substrate is placed in a specific cavity (S1') of the active-site groove while the P1 residues and on extend into a mostly hydrophobic area of the groove (in pockets S1, S2, etc.). The scissile peptide bond is held in place with several polar interactions between protein side groups. The nitrogen atom on the C-terminal side is anchored to the nearby guanidine groups of arginine molecules. On the N-terminal side, the nitrogen atom is held by hydrogen bonds with tyrosine while the carbonyl group is held by hydrogen bonds with lysine. These interactions stretch the peptide bond and set it up for the water molecule to break it apart. While there are technically two active sites on the tetramer, one on each active subunit, only one active site can be used at a time.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.